期刊文献+

替硝唑在汉族健康人体的药动学 被引量:3

Pharmacokinetics of Tinidazole in Chinese Healthy Volunteers
在线阅读 下载PDF
导出
摘要 目的研究汉族健康志愿者单剂量po替硝唑片的药动学。方法健康志愿者10名(其中男性5名,女性5名),单剂量po替硝唑片剂1 g,采用高效液相色谱法测定血浆中替硝唑的含量。用DAS软件程序进行数据处理,用SPSS软件对不同性别药动学参数进行统计分析。结果受试者单剂量po1 g替硝唑的主要药动学参数:ρmax为(19.04±2.42)mg·L-1,tmax为(2.15±0.47)h,t1/2为(16.94±2.40)h,AUC0-72 h为(454.37±59.74)mg·h·L-1,AUC0-∞为(486.14±65.63)mg·h·L-1。结论汉族健康志愿者单剂量po替硝唑片的体内药动学过程符合一室模型。经统计学分析,汉族健康志愿者药动学过程存在性别差异。 OBJECTIVE To study the pharmacokinetics of tinidazole tablets after a single oral dose in Han healthy volunteers.METHODS Five healthy male volunteers and five healthy female volunteers were involved in the study.Each subject received a single dose of 1 g tinidazole tablets.The plasma concentration was determined by HPLC.The pharmacokinetic parameters were calculated by DAS software and were statistical analyzed by SPSS software.RESULTS The main pharmacokinetic parameters were as follows: ρmax was(19.04±2.42) mg·L-1,tmax was(2.15±0.47) h,t1/2 was(16.94±2.40) h,AUC0-72 h was(454.37±59.74) mg·h·L-1,AUC0-∞ was(486.14±65.63) mg·h·L^-1.CONCLUSION The results showed that the plasma concentration-time curve of tinidazole were fitted to an one-compartment model and the main pharmacokinetic parameters of tinidazole have significant differences between male and female volunteers.
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第17期1336-1338,共3页 Chinese Pharmaceutical Journal
基金 全军医学科学技术研究“十一五”计划科技攻关课题基金资助项目(06G023)
关键词 替硝唑 高效液相色谱法 药动学 tinidazole,HPLC,pharmacokinetics
作者简介 郭涛,男,主任药师,博士生导师Tel:(024)23994860 E—mail:sy_guotao@263.net
  • 相关文献

参考文献7

  • 1DAI D Y. Manual of Practical New and Special Medicine(实用新药特药手册)[M]. Beijing: People' s Military Medical Press,2005:235-237.
  • 2SHENJP ZHANGL DINGHB etal.Pharmacokinetics and bioequiavailability of tinidazole capsule .广东药学院学报,1999,15(4):274-276.
  • 3ROBSON R A, BARLEY R R, SHARMAN J R. Tinidazole pharmacokinetics in severe renal failure [ J ]. Clin Pharmacokinet, 1984, 9( 1 ) :88-94.
  • 4PHILIP C, ALTON K B, SAMPSON C. Pharmacokinetics of tinidazole in male and female subjects[ J]. J Clin Pharmacol, 1982, 22( 11 ) :562-570.
  • 5杨积平,许善初.性别对药动学的影响[J].中国药房,2005,16(15):1188-1190. 被引量:25
  • 6FUNG H B, DOAN T L Tinidazole: A nitroimidazole antiprotozoal agent [ J ]. Clin Ther, 2005, 27 ( 1:2 ) :1859-1884.
  • 7PARKINSON A, MUDRA D R, JOHNSON C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocyles[ J]. Toxicol Appl Pharmacol, 2004, 199 (3) :193-209.

二级参考文献20

  • 1Gorski J, Jomes D, Haehner - Daniels B, et al . The contribution of intestinal and hepatic CYPaA to the interaction between medazolam and clarithromycin[J ]. Clin Pharmacol Tiler, 1998,64(2) : laa.
  • 2Krecic -Shepard M,Barnas C,Slimko J ,et al .Genderspecific effects on verapamil pharmacokinetics and pharmacodynamics in humans[J] .J Clin Pharmacol,2000,40(3) : 219.
  • 3Rohatagi S, Calic F, Harding N, et al . Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (AD1 628) after single and repeated administration in healthy male and female subjects and asthmatic patients[J ] .J Clin Pharmacol,2000, 40(11) : 1 211.
  • 4Greenblatt D,Wright C.Clinical pharmacokinetics of alprazolam: therapeutic implications[J ] . Clin Pharmacokinet , 1993,24(6) : 453.
  • 5Ducharme M, Slaughter R, Edwards D. Vancomycin pharmacokinetics in a patient population: effects of age,gender, and body weight [J ]. Ther Drug Monit, 1994,15(5):513.
  • 6Frame B, Facca B, Nicolau D, et al .Population pharmacokinetics of continuous infusion ceftazidime[J ] . Clin Pha rmacokinet, 1999,37(4) : 343.
  • 7Reigner BG,Welker H. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies[J ] .Antimicrob Agents Chemother , 1996,40(3) : 575.
  • 8Yukawa E, Mine H ,Higuchi S, et al .Digoxin population pharmacokinetics from routine clinical data:roles of patient characteristics for estimating dosing regiments[J ] .J Pharm Pharmacol , 1992,44(9) : 761.
  • 9Godfrey C,Sweeney K, Miller K, et al .The population pharmacokinetics of long - term methotrexate in rheumatoid arthritis[J ] .Br J Clin Pharmacol, 1998,46(4) :369.
  • 10Gaudry S,Sitar D,Smyth D,et al .Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine[J].Clin Pharmacol Ther,1993,54(1) : 23.

共引文献24

同被引文献1969

  • 1芮建中,张震,李金恒.群体药代动力学/群体药效动力学原理及研究方法[J].医学研究生学报,2005,18(3):246-249. 被引量:34
  • 2张军,居文政,刘史佳,刘芳.健康人体内替硝唑片的药代动力学及生物等效性研究[J].中国药物与临床,2005,5(12):906-909. 被引量:3
  • 3师少军,李忠芳,万元胜,曾繁典,陈华庭.塞克硝唑片在健康人体的药动学及生物等效性[J].中国医院药学杂志,2006,26(11):1350-1353. 被引量:2
  • 4BAIGR HUYM.Pharmacology and clinical application of tinidazole .中国药房,1998,9(1):42-43.
  • 5WEI S L, Zhang Q. Biopharmaceutics and Pharmacokinetics. Second Edition(生物药剂学与药动学.第二版)[M]. Beijing: Peking University Medical Press, 2004, 238-271.
  • 6US. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: Popalation pharmacokinetics[EB/Ok]. FDA, 1999: 1-31. htlp://www.fda.gov/ cber/gdins/popharm.htm.
  • 7ETTE E I. Stability and performance of a population pharmacokinetic model [J]. J Clin Pharmacol, 1997, 37(6): 486-495.
  • 8VOZEH S, MAITRE P O, STANSKI D R. Evaluation of population (NONMEM) pharmacokinetic parameter estimates [J]. J Pharmacokinet Biopharm, 1990, 18(2): 161-173.
  • 9SHEINER L B, BEAL S L. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares[J].J Pharmacokinet Biopharm, 1985, 13(2): 185-201.
  • 10SHEINER L B. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data [J]. J Pharmacokinet Biopharm, 1977, 5(5): 445-479.

引证文献3

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部